3CAI - Akt 抑制劑 - 生命科學(xué)試劑 - MedChemExpress_第1頁
3CAI - Akt 抑制劑 - 生命科學(xué)試劑 - MedChemExpress_第2頁
3CAI - Akt 抑制劑 - 生命科學(xué)試劑 - MedChemExpress_第3頁
3CAI - Akt 抑制劑 - 生命科學(xué)試劑 - MedChemExpress_第4頁
全文預(yù)覽已結(jié)束

下載本文檔

版權(quán)說明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請(qǐng)進(jìn)行舉報(bào)或認(rèn)領(lǐng)

文檔簡(jiǎn)介

1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemE3CAICat. No.: HY-16666CAS No.: 28755-03-5分式: CHClNO分量: 193.63作靶點(diǎn): Akt作通路: PI3K/Akt/mTOR儲(chǔ)存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性數(shù)據(jù)體外實(shí)驗(yàn) DMSO : 250 mg/mL (1291.12 mM; Need ultrasonic)Mass Solvent1 m

2、g 5 mg 10 mg Concentration制備儲(chǔ)備液1 mM 5.1645 mL 25.8224 mL 51.6449 mL5 mM 1.0329 mL 5.1645 mL 10.3290 mL10 mM 0.5164 mL 2.5822 mL 5.1645 mL請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度,選擇合適的溶劑配制儲(chǔ)備液,并請(qǐng)注意儲(chǔ)備液的保存式和期限。體內(nèi)實(shí)驗(yàn) 請(qǐng)根據(jù)您的實(shí)驗(yàn)動(dòng)物和給藥式選擇適當(dāng)?shù)娜芙獍?,配制前?qǐng)先配制澄清的儲(chǔ)備液,再依次添加助溶劑(為保證實(shí)驗(yàn)結(jié)果的可靠性,體內(nèi)實(shí)驗(yàn)的作液,建議您現(xiàn)現(xiàn)配,當(dāng)天使;澄清的儲(chǔ)備液可以根據(jù)儲(chǔ)存條件,適當(dāng)保存;以下溶劑前的百分 指該溶劑在您配制終

3、溶液中的體積占):1. 請(qǐng)依序添加每種溶劑: 10% DMSO 40% PEG300 5% Tween-80 45% salineSolubility: 2.08 mg/mL (10.74 mM); Clear solution2. 請(qǐng)依序添加每種溶劑: 10% DMSO 90% corn oilSolubility: 2.08 mg/mL (10.74 mM); Clear solutionBIOLOGICAL ACTIVITY1/3 Master of Small Molecules 您邊的抑制劑師www.MedChemE物活性 3CAI種有效的特異性 AKT1 和 AKT2 抑制劑。IC

4、50 & Target Akt1 Akt2體外研究 3CAI is a potential inhibitor of AKT. Based on these screening data, the effect of 3CAI on the kinase activitiesof AKT1, MEK1, JNK1, ERK1 and TOPK is tested using in vitro kinase assays. The results show that 3CAI (1M) suppresses only AKT1 kinase activity and the other kina

5、ses tested are not affected by 3CAI. 3CAI is amuch more potent AKT1 inhibitor than PI3K (60% inhibition at 1 vs 10 M, respectively). 3CAI substantiallysuppresses AKT1 activity as well as AKT2 activity in a dose dependent manner. 3CAI inhibits down-streamtargets of AKT and induces apoptosis. AKT-medi

6、ated phosphorlyation site of mTOR (Ser2448) and GSK3 (Ser9) are substantially decreased by 3CAI in a time-dependent manner. Furthermore, pro-apoptotic markerproteins p53 and p21 are also upregulated by 3CAI after 12 or 24 h of treatment. HCT116 and HT29 coloncancer cells are seeded on 6 cm dishes in

7、 1% FBS/McCoys 5A (HCT116) with 3CAI (4 M), I3C or the AKTinhibitor and then incubated for 4 days. Results show that the number of apoptotic cells is significantlyincreased by 3CAI in HCT116 and HT29 colon cancer cells compared with untreated control cells 1.體內(nèi)研究 To examine the antitumor activity of

8、 3CAI in vivo, HCT116 cancer cells are injected into the right flank ofindividual athymic nude mice. Mice are orally administered 3CAI at 20 or 30 mg/kg, I3C at 100 mg/kg, orvehicle 5 times a week for 21 days. Treatment of mice with 30 mg/kg of 3CAI significantly suppressesHCT116 tumor growth by 50%

9、 relative to the vehicle-treated group (p 1.PROTOCOLKinase Assay 1 The kinase assay is performed. Briefly, the reaction is carried out in the presence of 10 Ci of -32PATPwith each compound (e.g., 3CAI, 0.5, 1, 2 and 4 M) in 40 L of reaction buffer containing 20 mM HEPES(pH 7.4), 10 mM MgCl2, 10 mM M

10、nCl2, and 1 mM dithiothreitol. After incubation at room temperature for 30min, the reaction is stopped by adding 10 L protein loading buffer and the mixture is separated by sodiumdodecyl sulfate-polyacrylamide gel electrophoresis (SDS). The relative amounts of incorporatedradioactivity are assessed

11、by autoradiography 1.MCE has not independently confirmed the accuracy of these methods. They are for reference only.Cell Assay 1 HCT116 or HCT29 colon cancer cells are plated into 60-mm culture dishes (1105 cells/dish) and incubatedfor 1 day in medium containing 10% FBS. The culture medium is then r

12、eplaced with a 1% serum medium andcultured for 4 days with 3CAI (4 M), I3C or a commercial AKT inhibitor. The cells are collected bytrypsinization and washed with phosphate buffered saline (PBS). The cells are resuspended in 200 L ofbinding buffer. Annexin V staining is accomplished. The cells are o

13、bserved under a fluorescence microscopeusing a dual filter set for FITC and propidium iodide and then analyzed by flow cytometry 1.MCE has not independently confirmed the accuracy of these methods. They are for reference only.Animal Mice 1Administration 1 Athymic mice Cr:NIH(S), NIH Swiss nude, 6-9

14、wk old are divided into five groups: 1) untreated vehiclegroup (n=15); 2) 20 mg 3CAI/kg of body weight (n=15), 3) 30 mg 3CAI/kg body weight (n=15); 4) 100 mgI3C/kg of body weight (n=15); 5) no cells and 30 mg 3CAI/kg of body weight (n=15). HCT116 cells (31062/3 Master of Small Molecules 您邊的抑制劑師www.M

15、edChemEcells/100 L) are suspended in serum free McCoys 5A medium and inoculated subcutaneously into the rightflank of each mouse. 3CAI, I3C or vehicle is administered orally 5 times per week for 21 days. Tumor volumeis calculated. Mice are monitored until tumors reach 1 cm3 total volume, at which time mice are euthanizedand tumors are extracted.MCE has not independently confirmed the accuracy of these methods. They are for reference only.REFERENCES1. Kim DJ, et al. (3-Chloroacetyl)-indole, a novel allosteric AKT inhibitor, suppresses colon cancer growth in vitro and in vivo. Cancer

溫馨提示

  • 1. 本站所有資源如無特殊說明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請(qǐng)下載最新的WinRAR軟件解壓。
  • 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請(qǐng)聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
  • 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁內(nèi)容里面會(huì)有圖紙預(yù)覽,若沒有圖紙預(yù)覽就沒有圖紙。
  • 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
  • 5. 人人文庫網(wǎng)僅提供信息存儲(chǔ)空間,僅對(duì)用戶上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理,對(duì)用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對(duì)任何下載內(nèi)容負(fù)責(zé)。
  • 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請(qǐng)與我們聯(lián)系,我們立即糾正。
  • 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時(shí)也不承擔(dān)用戶因使用這些下載資源對(duì)自己和他人造成任何形式的傷害或損失。

評(píng)論

0/150

提交評(píng)論